Linda Yaccarino’s subsequent position after departing X as CEO shall be one other chief government position at eMed Inhabitants Well being, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting government at NBCUniversal however left to hitch X as CEO for 2 years, the place she managed to have a optimistic influence on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared method to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed stated in a press launch that they sought her out for her “simple means to barter new partnerships” — it definitely additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed beforehand produced a tech platform that was designed for use with at-home COVID-19 speedy antigen assessments, guiding customers by the method of administering these assessments correctly. Now eMed is concentrated on GLP-1s, the category of medication like Ozempic, which can be utilized for each weight administration and therapy of kind 2 diabetes.
“To be a pacesetter in right this moment’s healthcare market, corporations must have a fearless tenacity that enables them to not solely develop, however to even be courageous sufficient to step ahead and redefine a complete business,” Yaccarino stated in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final purpose of bettering world healthcare outcomes by our groundbreaking providers and platforms.”
